Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 7;12(1):65–74. doi: 10.1002/(SICI)1098-2825(1998)12:1<65::AID-JCLA11>3.0.CO;2-M

Bayer immuno 1™ PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum

Deborah L Morris 1,✉, Paul W Dillon 1, Donald L Very 1, Phillip Ng 1, Linda Kish 1, Joan L Goldblatt 1, Debra J Bruzek 2, Daniel W Chan 2, M Saber Ahmed 3, Deborah Witek 3, Herbert A Fritsche 3, Carol Smith 4, Delia Schwartz 4, Morton K Schwartz 4, Jennifer L Noteboom 5, Robert L Vessella 5, Kwok K Yeung 1, W Jeffrey Allard 1
PMCID: PMC6807852  PMID: 9484672

Abstract

The Bayer Immuno 1™ PSA Assay measures total PSA in human serum and demonstrates excellent performance with an interassay CV ≤ 3.4% and a biological detection limit of 0.03 μg/L. No significant interference from common hormonal and chemotherapeutic drugs, kallikrein, prostatic acid phosphatase, and trypsin, or elevated levels of total bilirubin, hemoglobin, triglycerides, and IgG was observed. The 95th percentile values for healthy individuals increased with age from 3.0 μg/L for males 50–59 years and 3.3 μg/L for males 60–69 years, to 4.6 μg/L for males ≥ 70 years. Clinical studies with retrospective samples demonstrated correspondence between serial measurements of PSA and clinical outcome for 98% of 159 prostate cancer patients. Clinical sensitivity for patients with clinical evidence of disease, untreated at the time of specimen draw, increased with increasing stage from 77.5–100%. Specificity of 60–70% for BPH and other benign urogenital diseases was consistent with previous findings. Bayer Immuno 1 PSA Assay values for 2131 specimens from healthy subjects and patients with prostate cancer, BPH, and other malignant and nonmalignant diseases correlated well with the Abbott IMx® PSA Assay over the range 0.0–6,238 μg/L (Y = 1.10 × + 0.02). The Bayer Immuno 1 PSA Assay provides automated ultrasensitive, precise, and equimolar measurement of total PSA in human serum. J. Clin. Lab. Anal. 12:65–74, 1998. © 1998 Wiley‐Liss, Inc.

Keywords: prostate‐specific antigen, immunoassay, tumor marker

References

  • 1. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate‐specific antigen. Invest Urol 17: 159–163, 1979. [PubMed] [Google Scholar]
  • 2. Belanger A, van Halbeek H, Graves HCB, et al.: Molecular mass and carbohydrate structure of prostate‐specific antigen: Studies for establishment of an international PSA standard. Prostate 27: 187–197, 1995. [DOI] [PubMed] [Google Scholar]
  • 3. Berg T, Bradshaw RA, Carretero OA, et al.: A common nomenclature for members of the tissue (glandular) kallikrein gene families. Agents and Actions 38: 19–25, 1992. [DOI] [PubMed] [Google Scholar]
  • 4. Lundwall A, Lilja H: Molecular cloning of human prostate‐specific antigen cDNA. FEES Lett 214: 317–322, 1987. [DOI] [PubMed] [Google Scholar]
  • 5. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli EE: Isolation, characterization and amino acid sequence of gamma‐seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 170: 111–130, 1987. [DOI] [PubMed] [Google Scholar]
  • 6. Watt KW, Lee PJ, M'Timkulu T: Human prostate‐specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166–3170, 1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Lilja H: A kallikrein‐like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899–1903, 1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Lilja H, Laurell CB: The predominant protein in human seminal coagulate. Scand J Clin Lab Invest 45: 635–641, 1985. [DOI] [PubMed] [Google Scholar]
  • 9. Lilja H, Christensson A, Dahlen U, et al.: Prostate‐specific antigen in serum occurs predominantly in complex with alpha‐1‐antichymotrypsin. Clin Chem 37: 1618–1625, 1991. [PubMed] [Google Scholar]
  • 10. Zhou AM, Tewaari PC, Bluestein BL, Caldwell GW, Larsen FL: Multiple forms of prostate specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal antibodies. Clin Chem 39: 2483–2491, 1993. [PubMed] [Google Scholar]
  • 11. Stamey TA: Second Stanford conferences on international standardization of prostate‐specific antigen immunoassays: September 1 and 2 1994. Urology 45: 173–184, 1995. [DOI] [PubMed] [Google Scholar]
  • 12. Graves HCB, Wehener N, Stamey TA: Comparison of a polyclonal and monoclonal immunoassay for PSA: Need for an international antigen standard. J Urol 144: 1516–1522, 1990. [DOI] [PubMed] [Google Scholar]
  • 13. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC: Prostate‐specific antigen as a marker for prostatic cancer: A monoclonal and a polyclonal immunoassay compared. Clin Chem 33: 1916–1920, 1987. [PubMed] [Google Scholar]
  • 14. Oesterling JE, Chan DW, Epstein JI, et al.: Prostate‐specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766–772, 1988. [DOI] [PubMed] [Google Scholar]
  • 15. Seamonds B, Yang N, Anderson K, Whitaker B, Shaw LM, Bellinger JR: Evaluation of prostate‐specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology 28: 472–479, 1986. [DOI] [PubMed] [Google Scholar]
  • 16. Lichtner DJ, Lange PH, Reddy PK, Moore L: Prostate‐specific antigen and local recurrence after radical prostatectomy. J Urol 144: 921–926, 1990. [DOI] [PubMed] [Google Scholar]
  • 17. Killian CS, Yang N, Emrich LJ, et al.: Prognostic importance of prostate‐specific antigen for monitoring patients with stages B2 to Dl prostate cancer. Cancer Res 45: 886–891, 1985. [PubMed] [Google Scholar]
  • 18. Killian CS, Emrich LJ, Vargas FP, et al.: Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 76: 179–185, 1986. [PubMed] [Google Scholar]
  • 19. Takayama TK, Vessella RL, Brawer MK, Noteboom J, Lange PH: The enhanced detection of persistent disease after prostatectomy with a new prostate‐specific antigen immunoassay. J Urol 150: 374–378, 1993. [DOI] [PubMed] [Google Scholar]
  • 20. Diamandis EP, Yu H, Melegos DN: Ultrasensitive prostate‐specific antigen assays and their clinical application. Clin Chem 42: 853–857, 1996. [PubMed] [Google Scholar]
  • 21. Vessella RL, Lange PH: Issues in the assessment of PSA Immunoassays. Urologic Clinics No Am 20: 607–619, 1993. [PubMed] [Google Scholar]
  • 22. Stamey TA: Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate‐specific antigen assays mislead clinicians. Clin Chem 42: 849–852, 1996. [PubMed] [Google Scholar]
  • 23. Chan DW, ed: Immunoassay Automation: An Updated Guide to Systems. Academic Press, San Diego, 1996, 145–166. [Google Scholar]
  • 24. Zhou Z, Ng PC, Very DL, Allard WJ, Yeung KK: Bayer Immuno 1TM PSA Assay measures both free and alpha‐ 1‐antichymotrypsin‐complexed prostate‐specific antigen on an equimolar basis. J Clin Lab Anal 10: 155–159, 1996. [DOI] [PubMed] [Google Scholar]
  • 25. Woodrum D, French C, Shamel LB: Stability of free prostate‐specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 48: 33–39, 1996. [DOI] [PubMed] [Google Scholar]
  • 26. Christensson A, Laurell C‐B, Lilja H: Enzymatic activity of prostate‐specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 194: 755–763, 1990. [DOI] [PubMed] [Google Scholar]
  • 27. Physicians'Desk Reference, Medical Economics Data Production Co., 48th ed. Montvale, NJ, 1994. [Google Scholar]
  • 28. Berkow R, Fletcher AJ, eds: The Merck Manual of Diagnosis and Therapy, 16th ed. Merck, Rahway, NJ, 1992, P 2580–2591. [Google Scholar]
  • 29. Palken M, Cobb DE, Warren BH, Hoak DC: Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volume in radical prostatectomy specimens. J Urol 143: 1155–1162, 1990. [DOI] [PubMed] [Google Scholar]
  • 30. Armbruster DA: Prostate‐specific antigen: Biochemistry, analytical methods, and clinical application. Clin Chem 39: 181–195, 1993. [PubMed] [Google Scholar]
  • 31. Oesterling JE: Prostate‐specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923, 1991. [DOI] [PubMed] [Google Scholar]
  • 32. Passing H, Bablok W: Comparison of several regression procedures for method comparison studies and determination of sample sizes: Application of linear regression procedures for method comparison studies in clinical chemistry, part II. J Clin Chem Clin Biochem 22: 431–445, 1984. [DOI] [PubMed] [Google Scholar]
  • 33. Stenmen UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate‐specific antigen and alpha‐1‐antichymotrypsin is the major form of prostate‐specific antigen in serum of patients with prostate cancer: Assay of complex improves clinical sensitivity for cancer. Cancer Res 51: 222–226, 1991. [PubMed] [Google Scholar]
  • 34. Christensson A, Bjork T, Nilsson O, et al.: Serum prostate‐specific antigen complexed to alpha‐1‐antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100–105, 1993. [DOI] [PubMed] [Google Scholar]
  • 35. Oesterling JE, Jacobsen SJ, Cooner WH: The use of age‐specific reference ranges for serum prostate‐specific antigen in men 60 years or older. J Urol 153: 1160–1163, 1995. [PubMed] [Google Scholar]
  • 36. Catalona WJ, Hudson MA, Scardino PT, et al.: Selection of optimal prostate‐specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2037–2042, 1994. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES